Icure Pharmaceutical Incorporation Logo

Icure Pharmaceutical Incorporation

Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.

175250 | KO

Overview

Corporate Details

ISIN(s):
KR7175250000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 봉은사로104길 10 7층, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Icure Pharmaceutical Incorporation is a biopharmaceutical company specializing in the research, development, and commercialization of products based on its Transdermal Drug Delivery System (TDDS) technology. Established in 2000, the company develops innovative new drugs, including transdermal patches for dementia and Parkinson's disease. Icure also operates a cosmeceutical business, leveraging its pharmaceutical expertise to offer Original Design Manufacturing (ODM) and Original Brand Manufacturing (OBM) services for cosmetics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상 결정)
Korean 4.9 KB
2025-09-17 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Korean 4.7 KB
2025-09-16 00:00
Capital/Financing Update
주요사항보고서(자기전환사채만기전취득결정)
Korean 14.7 KB
2025-08-27 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-22 00:00
Capital/Financing Update
주요사항보고서(자기전환사채만기전취득결정)
Korean 14.7 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 85.9 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.6 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-05 00:00
Legal Proceedings Report
횡령ㆍ배임혐의발생
Korean 8.7 KB
2025-08-05 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-08-05 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련 안내)
Korean 2.7 KB
2025-08-05 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.0 KB
2025-07-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 79.1 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.8 KB
2025-06-30 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.0 KB

Automate Your Workflow. Get a real-time feed of all Icure Pharmaceutical Incorporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Icure Pharmaceutical Incorporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Icure Pharmaceutical Incorporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.